Mourtas Spyridon, Papadia Konstantina, Kordopati Golfo G, Ioannou Panayiotis V, Antimisiaris Sophia G, Tsivgoulis Gerasimos M
Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26510 Rio Patras, Greece.
Department of Chemistry, University of Patras, 26510 Rio Patras, Greece.
Pharmaceutics. 2022 Aug 8;14(8):1649. doi: 10.3390/pharmaceutics14081649.
Arsonolipids represent a class of arsenic-containing compounds with interesting biological properties either as monomers or as nanostructure forming components, such as arsonoliposomes that possess selective anticancer activity as proven by in vitro and in vivo studies. In this work, we describe, for the first time, the synthesis of novel arsono-containing lipids where the alkyl groups are connected through stable ether bonds. It is expected that this class of arsonolipids, compared with the corresponding ester linked, will have higher chemical stability. To accomplish this task, a new methodology of general application was developed, where a small arsono compound, 2-hydroxyethylarsonic acid, when protected with thiophenol, can be used in an efficient and simple way as a building block for the synthesis of arsono-containing lipids as well as other arsono-containing biomolecules. Thus, besides the above-mentioned arsonolipid, an arsono cholesterol derivative was also obtained. Both ether arsonolipid and arsono cholesterol were able to form liposomes having similar physicochemical properties and integrity to conventional arsonoliposomes. Furthermore, a preliminary in vitro anticancer potential assessment of the novel ether arsonolipid containing liposomes against human prostate cancer (PC-3) and Lewis lung carcinoma (LLC) cells showed significant activity (dose- and time-dependent), which was similar to that of the conventional arsonoliposomes (studied before). Given the fact that novel arsonolipids may be more stable compared to the ones used in conventional arsonoliposomes, the current results justify further exploitation of the novel compounds by in vitro and in vivo studies.
砷脂是一类含砷化合物,无论是作为单体还是作为形成纳米结构的组分,都具有有趣的生物学特性,例如砷脂体,体外和体内研究已证明其具有选择性抗癌活性。在这项工作中,我们首次描述了新型含砷脂质的合成,其中烷基通过稳定的醚键相连。预计这类砷脂与相应的酯连接的砷脂相比,将具有更高的化学稳定性。为完成这项任务,开发了一种通用的新方法,即一种小的含砷化合物2-羟乙基胂酸,在用苯硫酚保护后,可以高效且简单地用作合成含砷脂质以及其他含砷生物分子的构建单元。因此,除了上述砷脂外,还获得了一种含砷胆固醇衍生物。醚砷脂和含砷胆固醇都能够形成具有与传统砷脂体相似的物理化学性质和完整性的脂质体。此外,对新型含醚砷脂脂质体针对人前列腺癌(PC-3)和Lewis肺癌(LLC)细胞的初步体外抗癌潜力评估显示出显著活性(剂量和时间依赖性),这与传统砷脂体(之前研究过)相似。鉴于新型砷脂可能比传统砷脂体中使用的砷脂更稳定,目前的结果证明通过体外和体内研究进一步开发这些新型化合物是合理的。